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ABSTRACT 
Objective: The present study was aimed at the fabrication and characterization of solid lipid based microspheres (SLM) of Ketoprofen (KPF) and 
comparing its anti-inflammatory potential with the marketed formulation. 
Methods: Stearic acid as a lipid and tween 20, 80, span 20 and 80 as surfactants (at various concentrations) were utilized for formulation of topical 
delivery. Microparticles were successfully fabricated (0.71-3.12 µm) by hot melt microencapsulation technique and were characterised by 
photomicroscope, FTIR, scanning electron surface morphology, particle size analysis, zeta potential, fluorescent microscopy and In-vitro drug 
release studies followed by In-vitro and In-vivo anti-inflammatory studies. 
Results: Results revealed that tween 80 resulted in exceptional KPF entrapment efficiency of 82.6% with spherical rough surface morphology. In-
vitro drug release showed the initial burst release of 47% upto 2h followed by sustained release of 70% for 12h. By employing drug release kinetic 
modelling, formulations were found to obey Higuchi model and Korsmeyer-Peppas model. Further the In-vitro permeation study of optimized gel 
formulation represented better drug uptake through rat skin in comparison to marketed product. Finally, SLMs were found to possess superior In-
vitro and In-vivo anti-inflammatory potentials when compared to marketed formulation.  
Conclusion: SLMs proved to be promising drug carrier system for KPF topical delivery as they possessed the desirable particle size with high ability 
for drug entrapment with sustained anti-inflammatory effect. 
Keywords: Ketoprofen, Solid lipid microsphere, Controlled release, Anti-inflammatory activity. 
 
INTRODUCTION 
Inflammation is a complex biological response of our body against 
external and internal stimuli such as; irritants, pathogens or 
damaged cells which results in irritation, redness, heat and pain [1, 
2]. This may results in disability and loss of normal body function, as 
commonly seen in osteoarthritis and rheumatoid arthritis [3]. 
Ketoprofen (KPF) is the potent NSAID (non steroidal anti-
inflammatory drug) which act as cyclooxygenase (COX) inhibitor. 
Therapeutically, it has been recommended for the treatment of 
typical arthritis or associated disorders as well as an effective anti-
inflammatory, antipyretic and analgesic agent [4, 5]. However, oral 
administration of KPF showed less therapeutic concentration in the 
joint cavity, as it undergoes "first-pass" metabolism [6]. Additionally 
KPF is associated with sever gastrointestinal side effects which 
include ulceration, gastrointestinal perforation and bleeding [7]. Due 
to short half-life of KPF, the frequency of dose increases in order to 
maintain its therapeutic concentration [8] resulting in increased 
associated side effects. In this context, an appropriate topical 
controlled release dosage form can be a better alternative choice in 
order to deliver KPF directly to the affected area.  
Topical delivery provides the suitable advantages to avoid the 
associated GIT side effects of an oral route as well as better patient 
compliance and bypasses first pass metabolism [9, 10]. In recent time, 
greater attentions have been devoted to polymeric based 
microparticles/microspheres and are widely investigated as suitable 
carriers for topical delivery [11]. Solid lipid microspheres (SLM) are 
well known for their advantageous properties such as 
biodegradability, physicochemical stability and higher hydrophobic 
drug molecule encapsulation efficiency [12, 13]. SLMs had shown 
exceptionally suitable for oral [14], pulmonary [15, 16] intramuscular 
and topical or subcutaneous delivery of drugs. Topical delivery 
possessed by SLMs is by virtue of their eminent affinity towards 
stratum corneum [17]. Moreover, non-ionic surfactants have been 
documented and utilized as those with the least toxicity and irritant 
index. These decisive properties make these agents as potential 
penetration enhancers in transdermal delivery systems [18]. 
In this present investigation, a SLM based drug delivery system of 
KPF for topical application was prepared and evaluated. In 
particular, we employed the non ionic surfactant, owing to its better 
spherical morphology for efficient drug release from the fabricated 
SLMs. Afterward physicochemical characterization of formulation 
was carried out in order to obtain optimised SLMs size and 
morphology with improved drug release profile. The best SLM 
formulation (Carbopol 934P based gel) was further subjected for In-
vitro and In-vivo anti-inflammatory screening. 
MATERIALS AND METHODS 
Material 
Ketoprofen (KPF) was obtained as a gift sample from Odian Health 
Care Pvt. Ltd. Solan, Himachal Pradesh (India). Carbopol 934P was 
provided by Qualikems Laboratory Reagents, Triethanolamine was 
purchased from Merck chemicals and carrageenan was purchased 
from Sigma Aldrich. Stearic acid, tween 20, tween 80, span 20 and 
span 80, potassium dihydrogen orthophosphate, sodium chloride 
and disodium hydrogen orthophosphate were purchased from 
Himedia. Methanol and ethanol absolute (purity>99.9%) was 
supplied by Merck Chemicals. Double distilled water was used for all 
experiments. All other reagents were of reagent grade and used as 
received without any purification. 
Fabrication of SLM  
SLMs were prepared by using hot melt microencapsulation 
technique (normal or phase inversion technique) with slight 
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modifications [19]. Briefly, stearic acid (lipid) was melted in a 
beaker at 70 °C. Weighed amount of KPF was dispersed in melted 
stearic acid under continuous stirring on magnetic stirrer to form 
hot melt mixture. Hot mixture was emulsified into an aqueous 
surfactant solution and was heated above lipid melting point to form 
oil/water emulsion. Four different surfactants (span 20, span 80, 
tween 20 and tween 80) were added in different concentrations as 
shown in table 1. The o/w emulsion was poured into 100 ml of ice-
cooled aqueous phase (2 °C–5 °C) and finally allowed to cool. 
Microspheres were allowed to settle down and after 15 min aqueous 
phase were decanted, microspheres were filtered, washed thrice with 
deionised water and freeze dried using Lyophilisor (Allied Frost FD-3).  
Physicochemical characterization 
Light microscopy 
Optical light microscopy was performed to visualize physical 
appearance of developed SLMs by using Olympus BX53 microscope 
at 20X and 100X magnification. Dried microspheres were placed on 
glass slide, glycerine drop was used to fix them onto the glass slide 
and the cover slip was placed on the top.  
Fourier transform infrared spectroscopy (FTIR) analysis  
FTIR spectra were determined (FTIR Instrument of Agilent Technologies 
630 Cary) in order to investigate possible drug-excipient chemical 
interactions or compatibility between the moieties. Spectra were 
obtained by running Micro Lab software and interpretation was made. 
Estimation of percent yield, drug loading and entrapment 
efficiency 
Lyophilized SLMs from each formulation were weighed and 
respective percentage yield (PY) was calculated by using equation 1. 
PY = Mass of the obtained microspheres
Initial mass of the drug+Initial mass of polymer
 × 100 (1) 
Drug entrapment efficiency was determined by lysis of SLM with 
ethanol using sonicator (citizone-ultrasonic-Model-YJ5120). 50 mg 
of SLMs were weighed and dissolved in 10 ml of ethanol and further 
subjected to sonication for 15 min to get the clear transparent 
solution. By using UV visible spectrophotometer (Systronics-Model-
2202), the concentration of KPF in ethanol was evaluated at 258 nm. 
Entrapment efficiency was determined for each batch in triplicate. 
Percentage entrapment efficiency (EE) and drug loading (DL) was 
calculated using equation 2 and 3.  
EE (%) = (Total  drug )–(Free  drug )
(Total  drug )
 × 100 (2)  
DL (%) = (Initial  drug )− (Free  drug )
(Mixed  Lipid )
 × 100. (3) 
Particle size distribution 
Beckman coulter Zeta sizer was used to determine particle size of 
various prepared microspheres. Lyophilized microspheres were first 
re-dispersed in de-ionised water and placed on the sampling rack. 
Type I-A dispersant was used to prevent the microsphere 
aggregation. Results provided are the average of triplicate analyses.  
Morphology study  
Surface morphology and shape of microscopes were observed by 
scanning electron microscopy (SEM-QUANTA 250, FEI Makers). 
Microspheres were mounted onto metal stubs using double-sided 
adhesive carbon conductive tap and placed inside the vacuum 
chamber. Moving electrons from tungsten filament were made 
incident to sample and surface morphology of SLMs was studied. 
Drug distribution inside the SLM 
Fluorescence microscopy (OLYPMUS BX53) was used to study 
distribution and internal, localization of drug into the matrix system 
of microspheres. For this, fluorescent Rhodamine B dye was selected 
and the same fabrication technique was used to develop Rhodamine 
B loaded SLMs. Rhodamine B was excited via a mercury lamp (550 
nm band pass filter) and images were captured by using Image pro 
plus software.  
In vitro release of KPF from SLM 
In vitro drug release from fabricated SLMs was determined by 
applying membrane diffusion technique (Franz diffusion cell) and 
using molecular porous membrane (Spectra/Por dialysis membrane 
12–14.000). Microspheres, equivalent to 10 mg of KPF, were 
suspended in 5 ml phosphate buffered saline (pH 7.4) and placed 
inside the conical flask having 100 ml of PBS as the dissolution 
medium. Apparatus was adjusted at constant speed (50 rpm) and 
temperature of 32 °C. Samples were collected after 15 min, 30 min, 
1, 2, 3, 4 h respectively and for every successive 2 h over a period of 
12 h and assayed spectro-photometrically (Systronics-Model-2202) 
at 258 nm. Release data was further subjected to mathematic 
modelling to determine the release profile. 
Mathematical modelling and drug release kinetics  
Data from in vitro drug release were fitted to kinetic equations to 
describe the mechanism of drug release from microspheres. The 
employed kinetic models were zero-order equation, first-order 
equation, Higuchian and Korsmeyer–Peppas. Zero-order kinetics 
(eq. 4) depicts the linear relationship in between the released drug 
and time. First-order Kinetics (eq. 5) shows the correlation between 
the release amount of drug and the remaining drug to be released. 
Higuchi model [20, 21] gives the expression for the released drug 
which depends on the square root time (eq. 6). Rate constants for 
the respective models were calculated and to check out the further 
drug release mechanism, initial 60% of drug release were fitted in 
Korsmeyer–Peppas [22] models represented in equation 7. 
Qt
ln Q
= k0t............................................ (4) 
t  = ln Qα+k1
Q
t............................. (5) 






t is the released amount of drug at time t, Qα is initial amount 
of drug, were as k0, k1, k  h  and k  k
Preparation of ketoprofen loaded SLMs gel 
 are the corresponding release rate 
constants for zero-order, first-order Higuchian and Korsmeyer-
Peppas model respectively and n is diffusion exponent for 
Korsmeyer-Peppas. 
Dispersion method was used for preparation of KPF-SLMs gel. KPF 
encapsulated SLMs were incorporated into a gel base of Carbopol 
934P. Briefly, the gel was made by dispersing SLMs of KPF into 1% 
Carbopol 934P gelling solution to obtain 2.5% (w/w) gel under 
constant stirring. Few drops of triethanolamine were added as 
viscosity modifier or controller.  
Characterization of SLM gel 
pH, viscosity and spreadability 
The pH of prepared gel was measured using a digital pH meter 
(Systronics instruments, India). Gel viscosity via rotating 
measurement was determined by using Brookfield DV III ultra V 6.0 
RV cone and plate viscometer (Brookfield Engineering Laboratories, 
Middle-boro, MA) at 25+0.3 °C. Spreadability of prepared gels was 
determined by glass slide apparatus. Briefly, 10 grams of weight was 
attached to an upper slide and a thin layer of gel was placed in 
between the two slides, afterwards the time taken to separate 
completely one slide from other was noted [23]. 
Spreadability was then calculated by using the formula represented 
in equation 8. 
S = 𝑀𝑀×𝐿𝐿
𝑇𝑇
… … … …. (8) 
Where S is spreadability, M is the weight tide to upper slide, L is the 
length of glass slide, T as the time taken to separate slide completely 
from each other respectively. 
Preparation of skin for In-vitro permeation studies 
Rat abdominal skin was used for In-vitro permeation studies. 
Depilatory (hair removing cream) was applied on abdominal portion 
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of rat and hairs were completely removed from the skin. Afterward, 
abdominal skin was excised from rat with the help of the scalpel and 
fatty layer was removed by keeping skin in warm water at 60 °C. 
After 2 min, fatty layer was peeled off gently and skin was 
thoroughly washed with water and kept for saturation in phosphate 
buffer saline (pH 7.4) for 30 min.  
In-vitro skin permeation study of SLM gel  
In-vitro comparison studies were performed via investigating 
permeation of KPF-loaded-SLMs Gel and marketed KPF gel (Fastum-
Gel, India). The prepared skin was mounted on receptor 
compartment of modified Franz-diffusion cell with cross-sectional 
area of 3.91 cm2
Permeability co-efficient = steady −state  flux
drug  Initial  concentration  in donner  compartment
                         
.................(9) 
. Receptor compartment was filled with 42 ml of 
degassed phosphate buffer (pH-7.4) maintained at 37±0.5 °C with 
constant stirring at 50 rpm. Prior to application of formulations, skin 
was allowed to equilibrate according to conditions for 1 h. 
Formulated gel and marketed gel of KPF (2.5%) were applied 
uniformly on dorsal side of the skin. Aliquots of 2 ml were 
withdrawn periodically and replaced with the same amount of saline 
solution to maintain receptor phase volume at a constant level. 
Collected samples were quantified spectro-photometrically at a 
wavelength of 258 nm and all recording was made in triplicates. 
Steady state flux was calculate from slope of the plot using 
regression analysis [24] and permeability co-efficient (Kp) of the 
drug from membrane was calculated using equation 9. 
In-vitro evaluation of anti-inflammatory activity 
Inhibition of albumin denaturation 
Method from Mizushima et al., [25] was used for the evaluation of In-
vitro anti-inflammatory activity of SLM-loaded-KPF-Gel and 
marketed formulation with slight modifications. Briefly, 1 ml sample 
solution was withdrawn during In-vitro drug release study at 0, 0.5, 
1, 2, 4, 6, 8, 10 and 12 h, thereafter, subjected to In-vitro anti-
inflammatory analysis. For the purpose of control, equal volume of 
distilled water was used. To each reaction mixture, 1 ml of bovine 
albumin (1% in distilled water) was transferred and pH was 
adjusted to 6.3 by using small amount of 1N HCl. Samples were 
incubated for 30 min at 37 °C in the dark followed by incubation at 
57 °C for 5 min. Reaction tubes were then cooled under running tap 
water and turbidity of all the samples were recorded spectro-
photometrically (Systronics-Model-2202) in triplicate at 660 nm. 
Percentage inhibition of albumin denaturation was calculated by 
using equation 10. 
Percentage inhibition =Abs  Control –Abs  Sample
Abs  Control
 × 100 ............... (10) 
RBC membrane stabilization 
Preparation of red blood cells (RBCs) suspension 
Sufficient amount of fresh rat blood was collected in the glass tube 
having 1.8 mg/ml 5% EDTA solution and mixed gently. Blood sample 
was centrifuged at 3000 rpm for 15 min and washed thrice with 
equal volume of normal saline. 10% v/v suspension of RBC was 
prepared in normal saline. Suspension was stored at 4 °C and used 
within 6 h of preparation [26, 27]. 
RBC membrane stabilization method 
Reaction mixture consisted of 1 ml phosphate buffer, 2 ml hypo-
saline (0.36 %), 0.5 ml blood suspension and 1 ml of sample taken 
from In-vitro release study at 0, 0.5, 1, 2, 4, 6, 8, 10 and 12h 
respectively. Reaction mixture was incubated at 37 °C for 30 min, 
followed by centrifugation at 3000 rpm for 20 min. Collected 
supernatant was then subjected to spectrophotometric analysis at 
560 nm [28]. All the readings were taken in triplicate and 
percentage membrane stabilization was calculated by using 
equation 11. 
Percentage membrane stabilization = Abs Control–Abs Sample
Abs Control
 × 100 
................... (11) 
In-vivo anti-inflammatory study 
In-vivo anti-inflammatory activity of selected SLM formulation was 
studied by carrageenan induced paw edema in male Wistar rats and 
was compared to marketed formulation. All the experiments were 
performed according to CPCSEA guideline and approval from 
Institutional animal Ethics Committee (IAEC/SU-PHAR/13/007). 
Animals weighing 130-150 g were divided into three groups and 
each containing five animals. Group I received a topical plane 
hydrogel, group II received marketed KPF-Gel and group III received 
SLM-loaded-KPF-Gel. 0.1 ml carrageenan solution (1% w/v in saline) 
was injected into sub-planter region of left hind paw of the rat and 
paw volume was measured after 0, 1, 2, 3, 4, 5, 6, and 12 h using 
plethysmometer. The edema rate and inhibition rate of each group 
were calculated by assigning equation 12 and13. 
Edema Rate (E%) = Vt−Vo
Vo
 × 100 ....................... (12) 
Inhibition Rate (I%) = Ec−Et
Et
 × 100 .................... (13) 
Where Vo is the mean paw volume before carrageenan injection 
(ml), Vt is the mean paw volume at different time internal (ml), Ec is 
the edema rate of control group, and Et is the edema rate of the 
treated group. 
RESULTS AND DISCUSSION 
Optical microscopy 
Fig. 1 represents the optical microscopic images of drug loaded and 
blank microspheres revealing the spherical shape, discrete and 
uniform microspheres with negligible aggregation. Fig. 1 (a, c) depict 
the blank microspheres, whilst Fig. 1 (b, d) present the microscopic 
image of drug loaded microspheres at 20X and 100X magnification 
respectively. 
FTIR analysis 
Drug-excipient interactions were studied by FTIR spectral analysis. 
FTIR spectroscopy confirms the structural stability of KPF inside 
microspheres and compatibility between drug and stearic acid. FTIR 
spectra of pure drug, stearic acid and KPF-loaded-SLMs are 
presented in fig. 2. FTIR spectrum of stearic acid (fig. 2a) showed 
prominent band at 1700 cm-1 corresponding to C=O (stretching) and 
peaks at 2916 cm-1 and 2849 cm-1 were corresponded to–CH-bond 
having saturated carbon atoms. FTIR of KPF (fig. 2b) showed band of 
C=O stretching at 1695 cm-1, aromatic C=O stretching at ~ 1655 cm-1 
and 1595 cm-1,-CH-deformation of aromatic ring ~ 860 cm-1 and 690 
cm-1
Percentage yield (PY), drug loading (DL) and percentage 
entrapment efficiency (EE)  
. These representative bands of KPF appeared with substantial 
compatibility of KPF-loaded-SLMs (fig. 2c) revealing that KPF is 
stable within SLMs without any kind of chemical interaction.  
PY, DL and EE of all the batches of KPF-loaded SLMs were performed 
in triplet and the corresponding values have been listed in table 2. 
PY values were found within the range of 73% to 91% respectively. 
It was observed that EE increases with increase in concentration of 
stabilizer, i.e. from 0.5 ml to 1.5 ml irrespective of surfactant type 
used. Interestingly, with the increase in surfactant concentration, 
solubility of drug inside lipid was enhanced. Similar results were 
obtained with other stabilizers. Formulations showed EE value 
ranging between 39.04%-82.61% (table 2) and highest entrapment 
efficiency was found to be with Tween 80 (F4; 82.61%). 
Formulations comprising span showed comparatively lower EE to 
others, moreover span 80 depict lower most EE compared to span 
20. This can be explained in context to higher HLB value for span 20 
than span 80. In case of tween, HLB does not play a major role as it is 
dominated by the stability of an emulsion system and it was found 
that tween 80 gives the more stable emulsion system in comparison 
to tween 20. In addition, the stability was observed for 30 d, where 
tween 80 was found better without any kind of clump formation and 
phase inversion. Hence the entrapment efficiency of different 
formulations were observed in following order; tween 80>tween 
20>span 20>span 80, respectively. Similarly, DL also represents the 
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same pattern, with increase in amount of surfactant volume; DL also 
increases and varies from 38 % to 21 % (table 2). Based on the 
highest EE, four different formulations from each surfactant class 
(F1, F4, F7 and F10) were selected and subjected for further studies. 
  
 
Fig. 1: Optical microscopic images of solid lipid microspheres; 
(a) blank SLMs in bulk, (b) drug loaded SLMs in bulk, (c) 
individual blank microsphere and (d) individual drug loaded 




Fig. 2: FTIR spectrum of (a) stearic acid, (b) pure drug and (c) 
KPF-Loaded-SLMs 
 
Surface morphology and particle size 
Based on entrapment efficiency, scrutinized formulations (F1, F4, F7 
and F10) were evaluated for surface morphology and particle size 
distribution. Fig.3 display the representative SEM of selected SLMs 
and it clearly shows that formulations have spherical morphology 
with rough surface (scale bar = 50 µm). Selected formulations were 
further investigated for particle size distribution and corresponding 
curve for subjected formulations F1, F4, F7 and F10 has been 
presented in fig. 3a, b, c and d, respectively.  
Size distribution for all formulations was found in narrow range 
between 3.12±0.47 µm to 0.71±0.21 µm (fig. 3) suggesting them to 
be a suitable candidate for the topical route. Escribano and co-
workers reported that the particle size less than 3 µm gets randomly 
distributed in stratum corneum and penetrates skin easily [29]. 
Polydispersity Index (PDI) values were found to vary from 
0.293±0.18 to 0.533±0.06 (table 3) depicting uniformity in the 
particle size distribution.  
Drug distribution  
Rhodamine B fluorescent dye was used for drug distribution 
analysis. When light of the particular wavelength from mercury lamp 
(550 nm band pass filter) made incident to surface of the dye loaded 
microspheres, dye molecules absorbs light, gets excited and emit 
light for longer duration. This emitted light was being captured and 
visualized as coloured particles. Fig. 4 represents fluorescence 
images of microspheres displaying drug distribution inside the 
matrix of SLM. Fig. 4a shows SLM-loaded-Rhodamine B under bright 
field mode. Colour distribution of dye inside the sphere is attributed 
to uniform distribution of drug (identified by the intense red colour). 
It was observed that dye was well encapsulated and distributed up 
to the core of the microsphere (fig. 4 b, c). 
 
 
Fig. 3: SEM micrographs and corresponding diameter 
distribution histogram of SLMs; (a) F1-Tween 20 (1.5 ml), (b) 
F4-Tween 80 (1.5 ml), (c) F7-Span 20 (1.5 ml) and (d) F10-Span 
80 (1.5 ml). All scales (a-d) are 50 µm respectively 
Sharma et al. 




Fig. 4: Fluorescence micrographs represent the distribution of dye into the premises of Rhodamine–loaded SLMs; (a) Bright field showing 
microspheres in bulk, (b) Fluorescent image of microspheres in bulk and (c) individual microsphere. The images in (a), (b) are at 20X and 
(c) at 100X magnification 
 
 




Fig. 6: The Comparative permeation profile of drug for KPF-loaded SLMs gel and marketed gel 
 
 
Fig. 7: In-vitro % inhibition of albumin denaturation by marketed product (a) SLM-loaded KPF gel and (b) In-vitro % RBC membrane 
stabilization profile of marketed product and SLM-loaded KPF gel 
Sharma et al. 
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In-vitro release study of KPF from SLMs 
Percent cumulative In-vitro release of KPF for F1, F4, F7 and F10 has 
been depicted in fig. 5a. Selected formulations showed an initial 
burst release of 33-47 % (of total drug) within 2h followed by a slow 
and steady release of KPF up to 12h. Initial burst release of drug 
from microspheres is due to loosely associated drug molecules 
embedded in the surface layer of microspheres. Surface-associated 
drugs molecules are widely known to be the main cause for the 
initial burst release. Among all studied formulations, highest 
cumulative release was obtained for F4 approximately 70% within 
12 h (1.5 ml Tween 80 as stabilizer).  
Further, to gain better understanding of the release mechanism, In-
vitro release kinetics (mathematic modelling) was applied. Release 
constants were calculated from the slope of appropriate plots and 
regression coefficient (R2
From the results, it was found that formulation F1, F4, F7 and F10 
have the highest EE and particle size ranges between 0.7±0.21–
3.1±0.47 µm, but amongst four formulations F4 was found to have 
narrow particle size distribution, and lowest PDI. In addition, EE of 
F4 was found to be 82.61 %, whereas for F1, F7 and F10 were 61%, 
57.72% and 53.42%, respectively. The In-vitro release profile of F4 
was found to be much controlled in comparison to other 
formulations. Therefore, formulation F4 was chosen for further 
investigation.
) were determined by linear regression 
analysis. First order release data of formulations was found in a 
range of 0.388-0.564 and 0.726-0.921 for zero order respectively 
(table 4). The release regression values (correlation coefficient 
values) were best fit within Higuchi plot (0.901-0.998) in 
comparison to first and zero orders (table 4). Thus, the drug release 
of KPF was found to be proportional to square root of time, 
suggesting that all formulations followed diffusion controlled release 
mechanism (fig. 5b). Similarly, drug release mechanism was also 
studied by applying Korsmeyer-Peppas model and exponent values 
were found to lie between 0.249-0.360. The n values were found to 
be less than 0.5 indicating Fickian release (table 4).  
  
Table 1: Composition of anti-inflammatory KPF microspheres 
Formulation code F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
Ketoprofen (mg) 400 400 400 400 400 400 400 400 400 400 400 400 
Stearic acid (g) 2 2 2 2 2 2 2 2 2 2 2 2 
Tween 20 (ml) 1.5 1 0.5 ---- ---- ---- ---- ---- ---- ---- ---- ---- 
Tween 80 (ml) ---- ---- ---- 1.5 1 0.5 ---- ---- ---- ---- ---- ---- 
Span 20 (ml) ---- ---- ---- ---- ---- ---- 1.5 1 0.5 ---- ---- ---- 
Span80 (ml) ---- ---- ---- ---- ---- ---- ---- ---- ---- 1.5 1 0.5 
 
Table 2: Percentage yield, entrapment efficiency, drug loading within prepared SLM 
Formulation code PY (%) DL (%) EE (%) 
F1 73.52+0.32 35.42±0.25 61.45+0.72 
F2 79.30+0.41 28.61+0.18 56.26+0.22 
F3 84.50+0.34 24.53+0.27 47.07±0.37 
F4 87.58+0.52 38.48±0.31 82.61+0.73 
F5 91.90+0.24 32.72+0.22 79.53+0.33 
F6 83.41+0.27 25.63+0.45 72.53±0.48 
F7 78.62+0.12 32.21±0.46 57.72+0.46 
F8 81.66+0.56 27.49+0.35 52.54+0.57 
F9 86.91+0.43 21.36+0.43 46.14±0.39 
F10 73.33+0.42 34.10±0.33 53.42+0.28 
F11 82.08+0.31 31.67+0.31 49.11+0.27 
F12 83.75+0.48 26.37+0.28 39.04±0.44 
All values represent mean±SD, n=3,  
Abbreviation: PY-Percentage Yield, DL-Drug Loading, EE-Drug Loading 
 
Table 3: Poly-dispersity index of formulated KPF-SLMs 
Formulation code PDI 
F1 0.533±0.06 
F4 0.270±0.07  
F7 0.293±0.18 
F10 0.297±0.03 
All values represent mean±SD, n=3,  
Abbreviations: PDI-Poly-dispersibility Index 
 
Table 4: Correlation coefficient (r), reaction rate constants (k) and diffusion exponent (n) of the model equations applied to the release of 
drug from KPF-loaded SLMs 
Formulation code Zero order First order Higuchi Korsmeyer-peppas 
R K2 R0 K2 R1 k2 RH n 2 
SLM1 0.796 4.3872 0.450 0.036 0.953 17.59 0.461 0.301 
SLM 2 0.726 4.597 0.388 0.032 0.901 18.79 0.313 0.249 
SLM 3 0.921 3.792 0.564 0.039 0.998 14.49 0.568 0.360 
SLM 4 0.899 4.408 0.544 0.039 0.992 16.99 0.547 0.340 
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Table 5: In-vitro drug permeation profile investigated for marketed gel and SLM gel 
Formulations Cumulative release (µg/cm2 Flux (µg/cm) 2 Permeability coefficient (cm/h) /h) 
Marketed gel 61.43±0.53 252.4 10.09 × 10-4 
SLM-KPF-Gel 82.37±0.46 327.3 13.17 × 10-4 
All values represent mean±SD, n=3 
 





0 1 2 3 4 5 6 12 
Control Edema Rate % 0 52.63±4.2 58.81±3.80 63.41±7.06 66.12±7.41 58.21±4.73 52.14±4.88 46.16±4.33 
Marketed 
Gel 
Edema Rate % 0 27.21±3.46 32.12±4.10
*** 




0 48.30 45.38 41.64 27.08 25.92 19.21 13.13 





0 37.79 40.89 42.89 43.88 44.82 43.86 52.08 
Values are the mean±SD of each group (n=3). Where ‘*’ represents P values versus untreated control. All treated groups were simultaneously 
compared via one-way ANOVA. Where *** P<0.001 and **P<0.01. 
 
Characterization of SLM Gel 
KPF-loaded-SLMs Gel was prepared by dispersion method and 
prepared gel formulation was characterized for various 
physicochemical parameters as discussed below. 
Homogeneity, pH, viscosity and spreadability 
Developed gel was tested for homogeneity by visual inspection and 
was found clear without any kind of aggregation. The pH of prepared 
gel was found to lie at ~ 5.4±1.32 representing compatible with skin 
pH and acceptability for topical application [30]. In view point of 
patient’s compliance, spreadability and extrudability of gel is 
considered as an important property which was also found to be 
appropriate. Spreadability was found to be 3.21+0.15 gcm/sec 
representing good spreadability. Viscosity is also an essential 
parameter as the release of drug from gel depends on viscosity. 
Obtained value of the viscosity was found to be 7188.43±16.7 cP and 
each value points represent as mean±S. D., n=3.  
In-vitro permeation study of SLM Gel 
The optimized formulation F4 was further investigated for In-vitro 
rat skin permeability study. Comparative study was performed 
between marketed gel, used as standard and the developed gel (F4) 
which was approximately 2.5 % (marketed product composition). 
The permeability of drug was calculated by plotting graph between 
percent drug permeated against time (fig. 6). Higher permeation rate 
was observed for SLM-loaded-KPF gel i.e. more than 80% of drug 
permeated within 24h in comparison to marketed gel (fig. 6). 
Permeability parameters such as steady-state flux and permeability 
coefficient were also found significantly higher for developed gel 
formulation than the standard (table 5).  
In-vitro anti-inflammatory activity 
In-vitro percent inhibition of albumin denaturation method was used 
to evaluate anti-inflammatory potential of SLM (fig. 7a). Results 
reveal that SLM-loaded-KPF Gel inhibited approximately 50 % of 
albumin denaturation within 2 h followed by steady sustained 
inhibition pattern (fig. 7a). This can be explained as a consequence 
of initial burst release of drug from microspheres followed by 
sustained release of drug from the particulate system. These results 
were better than those obtained for marketed drug which showed 
percent inhibition of 37% at 2 h. Likewise, from percent RBC 
membrane stabilisation assay (fig. 7b) it is clear that SLM-loaded-
KPF gel was able to stabilize more than 50 % RBCs within 2 h and 
70% membrane stabilization was achieved at 12 h in controlled 
manner. However marketed formulation results in 45 % of RBCs 
membrane stabilization observed at 2 h.  
In-vivo anti-inflammatory study 
Further In-vivo anti-inflammatory study was carried out to reveal 
the effect of prepared gel formulation in animals through 
carrageenan induced rat paw edema model. Initially inhibition rate 
for developed gel was found to be 37.79 % as shown in table 6. 
Percent edema inhibition was found to be better for SLM-loaded-
KPF Gel than marketed formulation. Throughout the study, 
inhibition rate was almost steady after 3h of drug application which 
can be explained in context to steady and sustained release of drug 
by 4h after an initial burst release. As sustained release is known to 
provide continues availability of drug to skin [31], here SLMs 
provides the sufficient surface area to facilitate contact of stratum 
corneum with drug, which ensure sustained release of the drug for 
longer duration of time. Empirically, high affinity is reported for In-
vivo distribution of lipid particulate system inside the skin by no 
toxic effect and with non-irritant property [32].  
CONCLUSION  
Conclusively, KPF loaded microspheres were formulated and impact 
of different surfactants at various concentrations were studied. 
Microspheres were found to have optimum particle size and 
spherical surface morphology with respect to topical delivery. 
Physicochemical analysis suggested the successful incorporation of 
the poor water-soluble drug KPF with superior entrapment 
efficiency i.e. 82%. In-vitro and In-vivo anti-inflammatory studies 
represented faster onset of action and prolonged effect of KPF in 
comparison to marketed product. Therefore, this study not only 
confirms successful fabrication of SLMs but also provides a hint to 
utilize SLMs to overcome the bioavailability for poor water soluble 
drugs for topical/superficial infections. 
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